The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients
Official Title: Open-Label, Phase II Trial of Immunological Response Rate, Safety, and Tolerability of THERATOPE® Vaccine in Subjects With Metastatic Breast Cancer Undergoing Treatment With Aromatase Inhibitors or Faslodex®
Study ID: NCT00046371
Brief Summary: The purpose of this study is to examine the immunological response rate to administration of the THERATOPE® vaccine in women with stable metastatic breast cancer who are being treated with aromatase inhibitors or Faslodex® and who do not require chemotherapy. Post-menopausal women on aromatase inhibitors or Faslodex® alone and pre-menopausal women on aromatase inhibitors plus luteinising hormone-releasing hormone (LH/RH)-agonist may be eligible to be enrolled. Patients must not have had radiotherapy or major surgery within four (4) weeks prior to entering the study. Information about the safety and tolerability of administration of the THERATOPE® vaccine will also be gathered during the course of the study.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
, Berkeley, California, United States
, San Francisco, California, United States
, Santa Monica, California, United States
, Jacksonville, Florida, United States
, Plantation, Florida, United States
, Port St. Lucie, Florida, United States
, Chicago, Illinois, United States
, Des Moines, Iowa, United States
, Billings, Montana, United States
, Morristown, New Jersey, United States
, Gastonia, North Carolina, United States
, Hickory, North Carolina, United States
, Cincinnati, Ohio, United States
, Columbus, Ohio, United States
, Houston, Texas, United States
, Norfolk, Virginia, United States
, Richmond, Virginia, United States